

**Supplementary Table 2.** The result of histology between pre- and post-bariatric intervention

Author (year)	No. of samples	Proportion difference (95% CI)			
		Steatosis (≥Grade 1)	Lobular inflammation (≥Grade 1)	Ballooning degeneration (≥Grade 1)	Fibrosis (≥F2)
<b>After 3–6 months</b>					
Aldoheyan et al. (2017) <sup>24</sup>	27	-0.44 (-0.68, -0.21)	-0.33 (-0.57, -0.09)	-0.11 (-0.31, 0.09)	-0.69 (-0.88, -0.50)
von Schönfels et al. (2018) <sup>21</sup>	257	-	-	-0.25 (-0.40, -0.10)	-
Overall		-0.44 (-0.68, -0.21)	-0.33 (-0.57, -0.09)	-0.20 (-0.33, -0.06)	-0.69 (-0.88, -0.50)
Heterogeneity - I <sup>2</sup>		-	-	18.3% (NA-NA)	-
P-value		-	-	0.269	-
<b>After 12–24 months</b>					
Barker et al. (2006) <sup>25</sup>	19	-	-0.84 (-1.01, -0.67)	-	-0.42 (-0.71, -0.13)
Caiazzo et al. (2014a) <sup>26,†</sup>	681	-0.25 (-0.30, -0.21)	-	-	-
Caiazzo et al. (2014b) <sup>26,†</sup>	555	-0.13 (-0.19, -0.07)	-	-	-
Esquivel et al. (2018) <sup>28</sup>	63	-0.34 (-0.47, -0.21)	-	-	-
Fazel et al. (2007) <sup>29</sup>	43	-	-	-	0.07 (-0.09, 0.23)
Furuya et al. (2007) <sup>30</sup>	18	-0.33 (-0.56, -0.11)	-0.17 (-0.36, 0.02)	-0.50 (-0.75, -0.25)	-0.11 (-0.31, 0.09)
Liu et al. (2007) <sup>33</sup>	39	-0.87 (-0.98, -0.76)	-0.26 (-0.46, -0.05)	-0.59 (-0.75, -0.43)	-0.08 (-0.31, 0.14)
Mathurin (2009) <sup>34,†</sup>	381	-	-	-	0.02 (-0.01, 0.06)
Mattar et al. (2005) <sup>35</sup>	70	-0.63 (-0.74, -0.51)	-0.33 (-0.46, -0.20)	-	-0.23 (-0.37, -0.09)
Moretto et al. (2012) <sup>37</sup>	78	-	-	-0.33 (-0.47, -0.20)	-0.05 (-0.14, 0.04)
Salman et al. (2020) <sup>41</sup>	94	-0.10 (-0.16, -0.03)	-0.35 (-0.47, -0.23)	-0.26 (-0.36, -0.15)	-0.39 (-0.52, -0.27)
Salman et al. (2021) <sup>42</sup>	67	-	-	-	-0.42 (-0.57, -0.27)
Chaim et al. (2020) <sup>27</sup>	30	-0.33 (-0.56, -0.11)	-0.20 (-0.43, 0.03)	-0.23 (-0.47, 0.01)	-0.03 (-0.27, 0.20)
Verrasto et al. (2023a) <sup>43</sup>	77	-	-	-	-0.31 (-0.45, -0.17)
Verrasto et al. (2023b) <sup>43</sup>	79	-	-	-	-0.27 (-0.41, -0.13)
Overall		-0.37 (-0.56, -0.19)	-0.36 (-0.56, -0.16)	-0.38 (-0.52, -0.24)	-0.18 (-0.28, -0.08)
Heterogeneity - I <sup>2</sup>		96.6% (95%–97.7%)	86.7% (73.2%–93.4%)	72.8% (32%–89.2%)	89.6% (83.8%–93.3%)
P-value		<0.001	<0.001	0.005	<0.001
<b>After 36–60 months</b>					
Caiazzo et al. (2014a) <sup>26,‡</sup>	681	-0.24 (-0.30, -0.19)	-	-	-
Caiazzo et al. (2014b) <sup>26,‡</sup>	555	-0.17 (-0.22, -0.11)	-	-	-
Kral et al. (2004) <sup>13</sup>	104	-0.36 (-0.45, -0.26)	-0.18 (-0.47, 0.11)	-	-0.35 (-0.59, -0.12)
Lassailly et al. (2020) <sup>32</sup>	180	-0.33 (-0.44, -0.21)	-0.81 (-0.87, -0.75)	-0.93 (-0.97, -0.89)	-0.43 (-0.52, -0.35)
Mathurin et al. (2009) <sup>34,‡</sup>	381	-	-	-	0.00 (-0.03, 0.04)
Meinhardt et al. (2006) <sup>36</sup>	50	-0.11 (-0.29, 0.07)	-	-	0.03 (-0.11, 0.16)
Russo et al. (2021) <sup>40</sup>	37	-0.54 (-0.71, -0.37)	-	-	-0.14 (-0.32, 0.05)
Overall		-0.29 (-0.39, -0.18)	-0.51 (-1.12, 0.11)	-0.93 (-0.97, -0.89)	-0.17 (-0.36, 0.02)
Heterogeneity - I <sup>2</sup>		82% (61.6%–91.5%)	94.2% (81.8%–98.2%)	-	95.9% (92.9%–97.6%)
P-value		<0.001	<0.001	-	<0.001

† and ‡ indicate same cohort with different follow-up time frame.